Review proposes testing retatrutide against clozapine-linked weight gain

The wire

1. 01A narrative review in Biomedicines argues for studying retatrutide in schizophrenia spectrum patients on clozapine or olanzapine, citing 24.2% mean weight loss at 48 weeks in a Phase 2 obesity trial.
2. 02Psychiatrists and prescribers managing antipsychotic-associated metabolic dysfunction currently rely on metformin and GLP-1 receptor agonists, which the authors call clinically meaningful but incomplete.
3. 03No randomized data exist in this population; the glucagon-driven energy expenditure rationale is presented explicitly as untested hypothesis, and company-reported Phase 3 figures of up to 28.7% are not peer-reviewed.

From the source

Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework

Biomedicines · 2026 Aug 31 · Kaczynski MM, Zureikat RM, Kaczynski MR et al.